Karen M. O’cAllaghan

Karen M. O’cAllaghan

Auto-generated profile, based on publicly available information

Karen M. O’cAllaghan

Department of Nutritional Sciences, King's College London, London, United Kingdom

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2024 in Nutrition Reviews
Verified
Journal Article
Open access
PDF file
WYWen-Chien Yang
Wen-Chien Yang
RCRamaa Chitale
Ramaa Chitale
KOKaren M O’cAllaghan
Karen M O’cAllaghan
CSChristopher Sudfeld
Christopher Sudfeld
ESEmily R Smith
Emily R Smith
Previous research linked vitamin D deficiency in pregnancy to adverse pregnancy outcomes. Update a 2017 systematic review and meta-analysis of randomized controlled trials (RCTs) on the effect of vitamin D supplementation during pregnancy, identify sources of heterogeneity between trials, and describe evidence gaps precluding a clinical recommendation. The MEDLINE, PubMed, Europe PMC, Scopus, Cochrane Database of Systematic Reviews, Web of Science, and CINAHL databases were searched. Articles were included that reported on RCTs that included pregnant women given vitamin D supplements as compared with placebo, no intervention, or active control (≤600 IU d–1). Risk ratios (RRs) and mean differences were pooled for 38 maternal, birth, and infant outcomes, using random effects models. Subgroup analyses examined effect heterogeneity. The Cochrane risk of bias tool was used. Included articles reported on a total of 66 trials (n = 17 276 participants). The median vitamin D supplementation dose was 2000 IU d–1 (range: 400-60 000); 37 trials used placebo. Antenatal vitamin D supplementation had no effect on the risk of preeclampsia (RR, 0.81 [95% CI, 0.43-1.53]; n = 6 trials and 1483 participants), potentially protected against gestational diabetes mellitus (RR, 0.65 [95% CI, 0.49-0.86; n = 12 trials and 1992 participants), and increased infant birth weight by 53 g (95% CI, 16-90; n = 40 trials and 9954 participants). No effect of vitamin D on the risk of preterm birth, small-for-gestational age, or low birth weight infants was found. A total of 25 trials had at least 1 domain at high risk of bias. Additional studies among the general pregnant population are not needed, given the many existing trials. Instead, high-quality RCTs among populations with low vitamin D status or at greater risk of key outcomes are needed. Benefits of supplementation in pregnancy remain uncertain because current evidence has high heterogeneity, including variation in study context, baseline and achieved end-line 25-hydroxyvitamin D level, and studies with high risk of bias. PROSPERO registration no. CRD42022350057.

18 April 2024 in British Journal of Nutrition
Verified
Journal Article
Closed access
PDF file
KOKaren M. O’cAllaghan
Karen M. O’cAllaghan
KNKatarzyna G. Nowak
Katarzyna G. Nowak
KDKathryn Dalrymple
Kathryn Dalrymple
LPLucilla Poston
Lucilla Poston
JRJessica Rigutto-Farebrother
Jessica Rigutto-Farebrother
UCUPBEAT Consortium
UPBEAT Consortium
Prenatal vitamin D deficiency is widely reported and may affect perinatal outcomes. In this secondary analysis of the UK Pregnancies Better Eating and Activity Trial, we examined vitamin D status and its relationship with selected pregnancy outcomes in women with obesity (BMI ≥ 30 kg/m2) from multi-ethnic inner-city settings in the UK. Determinants of vitamin D status at a mean of 17 ± 1 weeks’ gestation were assessed using multivariable linear regression and reported as percent differences in serum 25-hydroxyvitamin D (25(OH)D). Associations between 25(OH)D and clinical outcomes were examined using logistic regression. Among 1089 participants, 67 % had 25(OH)D < 50 nmol/l and 26 % had concentrations < 25 nmol/l. In fully adjusted models accounting for socio-demographic and anthropometric characteristics, 25(OH)D was lower among women of Black (% difference = −33; 95 % CI: −39, −27), Asian (% difference = −43; 95 % CI: −51, −35) and other non-White (% difference = −26; 95 % CI: −35, −14) ethnicity compared with women of White ethnicity (n 1086; P < 0·001 for all). In unadjusted analysis, risk of gestational diabetes was greater in women with 25(OH)D < 25 nmol/l compared with ≥ 50 nmol/l (OR = 1·58; 95 % CI: 1·09, 2·31), but the magnitude of effect estimates was attenuated in the multivariable model (OR = 1·33; 95 % CI: 0·88, 2·00). There were no associations between 25(OH)D and risk of preeclampsia, preterm birth or small for gestational age or large-for-gestational-age delivery. These findings demonstrate low 25(OH)D among pregnant women with obesity and highlight ethnic disparities in vitamin D status in the UK. However, evidence for a greater risk of adverse perinatal outcomes among women with vitamin D deficiency was limited.

14 November 2023 in BMJ Nutrition, Prevention & Health
Verified
Journal Article
Open access
PDF file
KOKaren M O'CAllaghan
Karen M O'CAllaghan
HQHuma Qamar
Huma Qamar
AGAlison D Gernand
Alison D Gernand
AOAk Onoyovwi
Ak Onoyovwi
SZStanley Zlotkin
Stanley Zlotkin
DRDaniel E Roth
Daniel E Roth
Background: Vitamin D may modify iron status through regulation of hepcidin and inflammatory pathways. This study aimed to investigate effects of maternal vitamin D supplementation on iron status in pregnancy and early infancy. Methods: In a trial in Dhaka, Bangladesh, women (n=1300) were randomised to one of five vitamin D3 regimens from 17 to 24 weeks’ gestation until 26 weeks postpartum (prenatal; postpartum doses): 0;0, 4200;0, 16 800;0, 28 000;0 or 28 000;28 000 IU/week. All participants received standard iron-folic acid supplementation. In this secondary analysis (n=998), we examined effects of prenatal;postpartum vitamin D on serum ferritin and other biomarkers of maternal iron status (transferrin saturation, total iron binding capacity, soluble transferrin receptor and hepcidin) at delivery, and infant ferritin and haemoglobin at 6 months of age. Using linear regression, we estimated per cent mean differences between each intervention group and placebo with 95% CIs, with and without adjustment for baseline ferritin or inflammatory biomarkers (C reactive protein and α-1-acid glycoprotein (AGP)). Results: At delivery, ferritin concentrations were similar between each intervention group and placebo in unadjusted (n=998) and baseline ferritin-adjusted analyses (n=992; p>0.05). Compared with placebo, AGP was lower in each intervention group (per cent difference (95% CI) = −11% (−21 to –1.0), −14% (−23 to –3.5) and −11% (−19 to –2.0) in the 4200 IU/week, 16 800 IU/week and 28 000 IU/week groups, respectively; n=779). In the subgroup of women with baseline 25-hydroxyvitamin D < 30 nmol/L, ferritin was lower in each intervention group versus placebo (−23% (−37 to –5.0), −20% (−35 to –1.9) and −20% (−33 to –4.1) in the 4200 IU/week, 16 800 IU/week and 28 000 IU/week groups, respectively; n=645); effects were slightly attenuated after adjustment for inflammation (n=510). There were no effects of vitamin D on other iron biomarkers among women at delivery or infants aged 6 months. Conclusion: These findings do not support improvement of iron status by vitamin D. The effect of prenatal vitamin D supplementation on ferritin may reflect an anti-inflammatory mechanism.

10 April 2023 in Pediatric Research
Verified
Journal Article
Open access
PDF file
ASAysha Sidiqi
Aysha Sidiqi
FFFarzana Fariha
Farzana Fariha
SSShaila S. Shanta
Shaila S. Shanta
ADAlison Dasiewicz
Alison Dasiewicz
AMAbdullah Al. Mahmud
Abdullah Al. Mahmud
KOKaren M. O’cAllaghan
Karen M. O’cAllaghan
Background: Given limited experience in applying the creatine-(methyl-D3) (D3Cr) dilution method to measure skeletal muscle mass (SMM) in young children, the feasibility of deployment in a fielding setting and performance of the method was assessed in a cohort of 4-year-old children in Dhaka, Bangladesh. Methods: Following D3Cr oral dose (10 mg) administration, single fasting urine samples were collected at 2–4 days (n = 100). Twenty-four-hour post-dose collections and serial spot urine samples on days 2, 3 and 4 were obtained in a subset of participants (n = 10). Urinary creatine, creatinine, D3Cr and D3-creatinine enrichment were analyzed by liquid chromatography–tandem mass spectrometry. Appendicular lean mass (ALM) was measured by dual-energy x-ray absorptiometry and grip strength was measured by a hand-held dynamometer. Results: SMM was measured successfully in 91% of participants, and there were no adverse events. Mean ± SD SMM was greater than ALM (4.5 ± 0.4 and 3.2 ± 0.6 kg, respectively). Precision of SMM was low (intraclass correlation = 0.20; 95% CI: 0.02, 0.75; n = 10). Grip strength was not associated with SMM in multivariable analysis (0.004 kg per 100 g of SMM; 95% CI: −0.031, 0.038; n = 91). Conclusions: The D3Cr dilution method was feasible in a community setting. However, high within-child variability in SMM estimates suggests the need for further optimization of this approach. Impact: The D3-creatine (D3Cr) stable isotope dilution method was considered a feasible method for the estimation of skeletal muscle mass (SMM) in young children in a community setting and was well accepted among participants. SMM was weakly associated with both dual-energy x-ray absorptiometry-derived values of appendicular lean mass and grip strength. High within-child variability in estimated values of SMM suggests that further optimization of the D3Cr stable isotope dilution method is required prior to implementation in community research settings.

24 March 2025 in The Journal of Nutrition
Verified
Journal Article
Open access
KOKaren M O’cAllaghan
Karen M O’cAllaghan
CFCeline Funk
Celine Funk
FFFarzana Fariha
Farzana Fariha
MNMarium H Nagaria
Marium H Nagaria
ADAlison Dasiewicz
Alison Dasiewicz
DRDaniel E Roth
Daniel E Roth
The 25-hydroxyvitamin D concentration (25(OH)D) at which parathyroid hormone (PTH) concentration plateaus has been considered to benchmark vitamin D deficiency. However, in young children, there is limited evidence for a suppression point in the 25(OH)D-PTH relationship or its relevance to bone mass accrual. To determine whether the threshold of 25(OH)D at PTH suppression in young children is corroborated by associations of 25(OH)D (or PTH) with bone mineral content (BMC) and areal bone mineral density (aBMD). In a cross-sectional secondary analysis of data from the BONe and mUScle health in Kids (BONUSKids) study of 4-year old children in Bangladesh, serum 25(OH)D and intact PTH (iPTH) were analyzed by liquid chromatography-tandem mass spectrometry and a chemiluminescent immunoassay, respectively. BMC and aBMD were measured by dual-energy X-ray absorptiometry. Associations between 25(OH)D, iPTH and bone outcomes (BMC, BMC z-score, aBMD and aBMD z-score) were modelled using multivariable-adjusted linear regression and spline models. Model fit was compared using AIC. Of 534 participants (51% female), 28% had 25(OH)D concentrations 6.7pmol/L. Model fit of the inverse relationship between 25(OH)D and iPTH was optimised with an inflection point at 25nmol/L (<25nmol/L: -0.16pmol/L per 1nmol/L increase in 25(OH)D; 95%CI: -0.22, -0.10; P<0.001), above which the slope attenuated (≥25nmol/L: -0.02pmol/L; 95%CI: -0.04, -0.003; P=0.019). However, the positive linear associations between 25(OH)D and bone mass outcomes were monotonic (P0.05 for all). Associations were similar in males and females. Among 4-year old children in Dhaka, Bangladesh, we did not identify a 25(OH)D threshold to define vitamin D deficiency based on its association with bone mass. However, efforts to raise 25(OH)D to ≥25nmol/L may be warranted based on the relatively strong inverse association of 25(OH)D with iPTH below this threshold. Clinicaltrials.gov #NCT03537443.

22 November 2024 in Public Health Nutrition
Verified
Journal Article
Open access
PDF file
MGMaimuna Gias
Maimuna Gias
HQHuma Qamar
Huma Qamar
FFFarzana Fariha
Farzana Fariha
AMAbdullah Al Mahmud
Abdullah Al Mahmud
PSPrakesh Shah
Prakesh Shah
KOKaren M O’cAllaghan
Karen M O’cAllaghan
Objective: Growth faltering is widespread in many low- and middle-income countries, but its effects on childhood bone mass accrual are unknown. The objective of this study was to estimate associations between length (conditional length-for-age z-scores, cLAZ) and weight (conditional weight-for-age z-scores, cWAZ) gain in three age intervals (ages 0–6, 6–12 and 12–24 months) with dual-energy X-ray absorptiometry-derived measures of bone mass (total body less head (TBLH) bone mineral content (BMC), areal bone mineral density (aBMD) and bone area) at 4 years of age. Design: Associations between interval-specific growth parameters (cLAZ and cWAZ) and bone outcomes were estimated using linear regression models, adjusted for maternal, child and household characteristics. Setting: Data collection occurred in Dhaka, Bangladesh. Participants: 599 healthy children enrolled in the BONe and mUScle Health in Kids Study. Results: cLAZ in each age interval was positively associated with TBLH BMC, aBMD and bone area at 4 years; however, associations attenuated towards null upon adjustment for concurrent height-for-age z-scores (HAZ) at age 4 years and confounders. cWAZ from 0 to 6 and 6 to 12 months was not associated with bone mass, but every sd increase in cWAZ between 12 and 24 months was associated with greater BMC (7·6 g; 95 % CI: 3·2, 12·0) and aBMD (0·008 g/cm2; 95 % CI: 0·003, 0·014) after adjusting for concurrent WAZ, HAZ and confounders. Conclusions: Associations of linear growth (birth to 2 years) with bone mass at age 4 years were explained by concurrent HAZ. Weight gain in the second year of life may increase bone mass independently of linear growth in settings where growth faltering is common.